1 |
<p>PLIVA's research into anti-inflammatory agents is divided into four programs. |
2 |
In three of the programs, Locally-acting steroids, Anti-inflammatory agents |
3 |
and Inhibitors of TNF-alpha secretion, compounds with excellent therapeutic |
4 |
activity in relevant disease models of asthma and rheumatoid arthritis have |
5 |
been identified.</p> |
6 |
<p>In the <b>Locally-acting steroids program</b>, molecules have been discovered |
7 |
that demonstrate efficacy similar or superior to currently marketed |
8 |
locally-acting steroids when applied |
9 |
locally.</p> |
10 |
<p>In the <b>Anti-inflammatory program</b>, compounds with excellent |
11 |
anti-inflammatory activity were discovered throughout the testing when applied |
12 |
orally. A new synthetic pathway, enabling the synthesis of a chemically pure |
13 |
compound and the initiation of a derivatization strategy, has been found and |
14 |
is being extensively utilized.</p> |
15 |
<p>In the <b>Inhibitors of TNF-alpha secretion program</b>, several classes of |
16 |
compounds have been discovered that inhibit the secretion of TNF-alpha <i>in |
17 |
vivo</i> and have demonstrated good activity in the animal model of rheumatoid |
18 |
arthritis. Additional derivatization may provide a development candidate with |
19 |
higher safety and no adverse events.</p> |
20 |
<p>Finally, in the <b>Tyrosine phosphorylation program</b>, a collaboration with |
21 |
<a href="http://www.signalpharm.com">Signal Pharmaceuticals</a> has been |
22 |
initiated.</p> |